Company Performance Metrics
Jeffrey Cleland: Co-Founder & CEOPast Role: GrayBug, President & CEO
Karl Trass: Vice President, Regulatory AffairsPast Role: Neurobiological Technologies, Vice President, Regulator Affairs & Quality Assurance
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.
Headquartered in Redwood City, California,
Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.
The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
